Neuroendocrine Carcinoma clinical trials at UC Health
2 in progress, 1 open to eligible people
open to eligible people ages 18 years and up
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.
at UCLA UCSD UCSF
Sorry, in progress, not accepting new patients
To assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced solid tumors.
at UCLA UCSF